Oxaliplatin
Product Images NDC 57277-002

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 57277-002). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanja Pharmaceuticals Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

100 mg Carton (100mg 20ml Carton Rev)

100 mg Carton (100mg 20ml Carton Rev)
This is a description of a medical product called Oxaliplatin Injection. It is manufactured by Alidec Pharmaceuticals Limited and contains the active ingredient Oxaliplatin in a sterile, aqueous solution. Each vial contains 100 mg/20 mL of Oxaliplatin Injection, which should be stored at 25°C and protected from light. The product should be used only for intravenous use and should not be mixed with or added to sodium chloride/chloride-containing solutions. Dosage and administration instructions are available in the package insert.*
FDA Label Image

Bottle 50 mg (50mg 5ml Bottle Rev)

Bottle 50 mg (50mg 5ml Bottle Rev)
The text is not readable.*
FDA Label Image

Figure 2 (DFS Kaplan-Meier)

Figure 2 (DFS Kaplan-Meier)
FDA Label Image

Figure 3 (DFS Kaplan-Meie)

Figure 3 (DFS Kaplan-Meie)
This appears to be a graph or chart showing the DFS (disease-free survival) probability in months for different treatment arms in a clinical trial. The X-axis shows the months and the Y-axis shows the DFS percentage. The treatment arms appear to be FOLFOX4 and LVoFU2 for Dukes C stage, and there is a Hasard Ratio percentage of 6% for G070. The may have missed some important details, but overall it seems to be a representation of clinical trial data.*
FDA Label Image

Figure 01 (Fig 01)

Figure 01 (Fig 01)
This is a chemotherapy regimen that includes two days of treatment. On day 1 and day 2, the patient will receive a bolus injection of 400 mg/m of 5-FU over 2-4 minutes. On day 1 and day 2, they will also receive a Leucovorin infusion - 200 mg/m on both days. On day 2, the Leucovorin infusion will be accompanied by a 600 mg/m infusion of 5-FU. Additionally, on both days, the patient will receive an 85mg/m injection of Oxaliplatin at various times throughout the day. The time intervals for Oxaliplatin injection are not completely clear.*
FDA Label Image

Figure 4 – Kaplan-meier (Fig 04)

Figure 4 – Kaplan-meier (Fig 04)
FDA Label Image

Structure (Structure 01)

Structure (Structure 01)
FDA Label Image

100 mg Vial (Vial 100mg Vial Rev)

100 mg Vial (Vial 100mg Vial Rev)
FDA Label Image

Vial 50 mg (Vial 50mg Rev)

Vial 50 mg (Vial 50mg Rev)
This is the label information of Oxaliplatin Injection USP, manufactured in India by NDC Pharmaceuticals Ltd. The injection comes in a 10 mL vial containing 50mg/10mL Oxaliplatin and water for injection. The solution is sterilized and preservative-free. It is recommended to store at 15-30°C. The package insert contains dosage and administration data, required dilution, and other instructions. The injection is meant for intravenous use only.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.